Abby's

Volume 8 Issue 2

Issue link: https://cp.revolio.com/i/1262303

Contents of this Issue

Navigation

Page 16 of 35

www.AbbysHealthFood.com - Issue 42 | Page 17 Lifetime risk is calculated by dividing 2003 population (290,850,005) by the number of deaths, divided by 77.6, the life expectancy of a person born in 2003. There's a 0.2% chance of dying from COVID-19 if you get it and if age 30-39. That's a 1 in 500 chance of dying from it if you get it. But that's probably the chance if you are under the care of a physician in an allopathic care setting, not if you're on natural meds. And the chance that you will get it is not 100% so it lowers the overall chance of dying from it to even less than 0.2%. But, let's just use the 1 in 500 number to give the benefit of the doubt that we are all going to get it and that we are all going to be treated allopathically. A 1 in 500 chance of dying from corona is less of a chance than dying from falling, MRSA, accidental poisoning, suicide, car accidents, flu, hospital infections, stroke, cancer, and heart disease! If driving your car is more hazardous than corona, then why the big hubub about it? Symptoms: fever (most common symptom), cough, myalgia (muscle pain), fatigue, sore throat, mucus production, headache, trouble breathing, haemoptysis (coughing up blood), diarrhea. If symptoms become unbearable, seek immediate medical attention! Complications: pneumonia, lymphopenia (low lymphocyte count), leucopenia (low white blood cell count), cardiac injury, kidney injury, shock, secondary infection, respiratory distress, RNAaemia, prolonged prothrombin time (blood taking too long to clot), elevated D-Dimer (byproducts of fibrinolysis), hypoxia (low O 2 ). Other Clinical Features: high plasma concentrations of IL1B, IL1RA, IL7, IL8, IL9, IL10, basic FGF, GCSF, GMCSF, IFNγ, IP10, MCP1, MIP1A, MIP1B, PDGF, TNFα, and VEG upon admission. Conventional Treatment: antivirals (oseltamivir, etc.), antibiotics, corticosteroids, ventialtion, nasal cannula, kidney transplant. Contraindications: ACE inhibitors & angiotensin receptor blocker meds may ↑ infect risk (Diaz et al.) MUST HAVES 1. Boost the immune system – Pick two of the following and double the doses recommended on the bottles or do the max dose the bottle suggests: echinacea, astragalus, mushrooms, cat's claw, zinc (hydroxychloroquine works by pushing zinc into the cells), vitamin A, C, D3, E, selenium, colostrum, multivitamin. Or pick one of the following and double the dose recommended on the bottle (but don't double the dose on the Source Naturals Wellness Formula): Bluebonnet Wellness Support, Solaray Under the Weather Plus, Source Naturals Wellness Formula, Megafood Acute Defense, or Gaia Quick Defense. These formulas have many immune boosting ingredients in one product. 2. Take antivirals studied against coronaviruses and/ or HIV (HIV-1-like inserts have been found in COVID-19)3 – Pick one of the following and quadruple the dose recommended on the bottle or pick two options and only double the dose on each bottle. Studied against coronaviruses: red algae, Artemisia annua (wormwood), thyme, oregano, licorice, nettle root, peppermint, horse chestnut, or quercetin. Studied against HIV: silver, spirulina, olive leaf, Artemisia annua, andrographis, elderberry, reishi. Other antivirals: shilajit, goldenseal, agarikon, lysine. I do not recommend high doses of garlic, only minimal to average doses as it thins the blood too much for this particular issue. 3. Reduce inflammation in the lungs (Dr.s use corticosteroids as part of their treatment of COVID-19) – Pick 1 of the following and double, triple, or quadruple the dose recommended on the bottle: boswellia, black seed oil, ginger, turmeric, rosemary, bromelain, pancreatin, green tea, tart cherry, white willow, omega 3s, etc. Or pick one of the following and double the dose recommended on the bottle: New Chapter Zyflamend, Crystal Star Inflama Relief, Life Seasons Inflamma – X, Michael's Recovery Zymes or Wobenzym. By Collin Gow COVID-19 Epidemiology, Clinical Features, Example Regimens COVID-19 Epidemiology, Clinical Features, Example Regimens

Articles in this issue

Links on this page

Archives of this issue

view archives of Abby's - Volume 8 Issue 2